Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfi ll criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced signifi cantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.
Human T-cell lymphotropic virus type 1 (HTLV-1) predominantly infects T cells and leads to a variety of clinical manifestations, the most important of which are HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia lymphoma (ATLL). HAM/TSP is characterized by back pain, leg weakness, hyperrefl exia of the inferior limbs, Babinski sign, and diffi culty in walking 1 . Urinary symptoms occur in up to 100% of patients with HAM/TSP, and overactive bladder (OAB) is the main autosomatic manifestation of HAM/TSP 2 . The main fi ndings of urodynamic studies in such patients are overactivity of the detrusor muscle followed by detrusor sphincter dyssynergia, but detrusor arefl exia has been documented in a small percentage of cases 3 . While HAM/TSP occurs in less than 5% of HTLV-1-infected subjects, OAB characterized by urgency and other urinary symptoms, such as nocturia and incontinence, occurs in up to 19% of HTLV-1-infected people who do not fulfi ll criteria for HAM/TSP 3 . Moreover, the urinary symptoms of OAB may be the fi rst manifestation of HAM/TSP 1, 4 . Urinary manifestations are important complaints of HTLV-1-infected patients that decrease their quality of life and ability to work 5, 6 . Some patients experience voiding dysfunction and underactivity of the detrusor or detrusor arefl exia that requires intermittent self-catheterization 6 . The relationship between HTLV-1 infection and OAB is well documented. The expanded disability status scale (EDSS) has been used to evaluate the degree of neurologic dysfunction caused by HTLV-1, and a direct correlation between EDSS scores and urinary dysfunction has been revealed 4 . Moreover, pro-viral load and the production of pro-infl ammatory cytokines that characterize HAM/TSP are also seem increased in patients with OAB without HAM/TSP 7, 8 . These data suggest that OAB is a common urologic fi nding of HAM/TSP that may precedes full-blown HAM/TSP.
While the prevalence and relevance of urinary symptoms in cases of HTLV-1 infection are well documented, little research regarding treatment has been conducted. In our clinic, we have observed that only 50% of patients with HTLV-1-associated OAB exhibit improvements in symptoms upon treatment with propantheline bromide. Up to now, there´s no study evaluating the effect of oxybutynin or another anticholinergic agent, much more selective for the bladder receptors, in these patients. A double-blind controlled study comparing propantheline bromide, placebo and oxybutynin in patients with overactive bladder without HTLV-1 did not reveal any signifi cant difference between the group that received propantheline bromide and those that received placebo 9 . In another study, among 39 patients with HAM/TSP who had received pulse therapy with methylprednisolone, improvement in motor disability was observed in more than 60% of cases, but no improvements in bladder dysfunction were noted 10 . Botulinum toxin A is a neuromuscular blocking agent that can promote weakness in the detrusor sphincter muscle and control symptoms of OAB, and has been used to treat idiopathic and neurogenic detrusor overactivity in patients with multiple sclerosis, spinal cord injury, and children with OAB due to myelomeningocele 11, 12 . In a double-blind clinical trial of multiple sclerosis patients, botulinum toxin A was not only more effective than placebo, but 60% of the patients who had received botulinum toxin A had no urinary loss for up to 12 weeks 11 . The aim of these case reports was to describe the effect of botulinum toxin A on the urinary manifestations of three patients with HTLV-1-associated OAB.
CASE REPORT
Demographic, clinical, urodynamic and cystoscopic data from three patients prior to botulinum toxin A treatment are given in Table 1 .
Diagnosis of HTLV-1 infection was based on the detection of antibodies by enzyme-linked immunosorbent assay and confi rmation by western blot. Moreover, all patients had HTLV-1 pro-viral loads detected in their peripheral blood mononuclear cells. All patients were female, and their ages ranged from 24 to 69 years. All patients had urinary complains for a long period. Patient 1 had nocturia and urgency for 10 years. Five years after her illness had started, she developed HAM/TSP. Voiding symptoms worsened, the post-voiding residual volume rose, and clean intermittent catheterization was introduced. The other two patients were admitted to the clinic after having HAM/ TSP for nine and 14 years, respectively. All patients had severe neurologic involvement with Osame scores (OMDS) greater than 5, and EDSS scores greater than 6. Detrusor overactivity was found in all three cases, and patients 1 and 3 also exhibited arefl exia in urodynamic studies (Figure 1 ). All three patients had previously been treated with oxybutynin at a concentration of 10 mg three times per day for at least two months with a poor response. Moreover, patients 1 and 3 had received oxybutynin by the intravesical administration route, which had failed to resolve symptoms in both cases. This study was approved by the Ethical Committee of the Federal University of Bahia, and all patients signed an informed consent forms. The patients were asked to provide daily urinary reports before and after therapy, and were submitted to urodynamic examination prior to therapy. Additionally, each month after therapy, the patients completed a questionnaire about their urologic manifestations and neurologic complaints. Two hundred units of botulinum toxin A (Botox®, Allergan, Irvine, CA) were diluted in 30mL of physiologic solution, and one mL of the solution was administered intravesically by cystoscopy in 30 different sites in the bladder. Urinary manifestations (frequency, nocturia, urgency, and incontinence), OAB scores (OABSS), bladder functional capacity, post-voiding residual volume, and duration of the response (time until the request of another treatment or return to previous OABSS) before and after onabotulinumtoxin type A administration are shown in Table 2 .
After therapy, outpatient visits were scheduled at one week, two weeks, one month, and every two months thereafter. Improvements were observed in the fi rst week and plateaued at one month. The information presented refers to the last visit after therapy. The data obtained were similar to the observations made after the fi rst month of therapy. The most signifi cant change observed was the disappearance of incontinence in all patients. The quality of life of the patients was greatly improved. With the exception of nocturia, which did not changed for patient 2, all other urinary manifestations either improved or disappeared. OABSS was also signifi cantly reduced in all patients. Prior to treatment, patient 3 used to have urinary loss of the entire urine volume of the bladder, suggesting a voiding pattern dependent on involuntary detrusor contraction. After the injection of botulinum toxin A, the bladder could retain a physiologic amount of urine.
DISCUSSION
Urinary complains that are mainly due to OAB are highly relevant manifestations in HTLV-1 infection. In the present study, we showed that application of intravesical botulinum toxin A at a dose of 200 units signifi cantly improved the urinary manifestations of three patients with symptoms of OAB. The objective of treating OAB is to reduce episodes of urinary loss and preserve upper urinary tract function by reducing the intravesical pressure. Several treatments for OAB have been administered via oral and intravesical routes, but have not resulted in long-term clinical improvement. Botulinum toxin A has been studied as a potential treatment for OAB, and although the sample size in the present study was somewhat limited, we could confi rm these previous reports in the literature 11 and demonstrate that botulinum toxin A could be a treatment choice for patients with HTLV-1-associated OAB that is refractory to conservative management.
The major indication of botulinum toxin A is for autonomic disorders such as muscle spasms. In such cases, patients usually need to use the drug every three months 12 . Therefore, we do not expect that a single application of botulinum toxin A will resolve for long-term urinary disorders related to HTLV-1 infection. However, the disappearance of some urinary symptoms and the signifi cant improvement in OABSS scores that were maintained for up to fi ve months provide support for future studies with a larger number of HTLV-1-infected patients.
In conclusion, onabotulinum toxin A was effective in controlling OAB symptoms for a signifi cant duration with minimum side effects. Studies including a greater number of patients and longer follow-up periods should be performed to confi rm these fi ndings.
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